We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.22B
1-Year Est. Return 242.83%
This Fund
S&P 500
This Quarter Est. Return
+14.97%
1 Year Est. Return
+242.83%
3 Year Est. Return
+1,579.88%
5 Year Est. Return
+1,852.28%
10 Year Est. Return
–
AUM
$1.22B
AUM Growth
+$188M
Cap. Flow
+$70.2M
Cap. Flow %
5.76%
Top 10 Hldgs %
90.48%
Holding
26
New
4
Increased
2
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
ALMR
Alamar Biosciences
ALMR
+$56.1M
2
PBLS
Parabilis Medicines Inc
PBLS
+$15.4M
3
ARTV
Artiva Biotherapeutics
ARTV
+$8.7M
4
IVA
Inventiva
IVA
+$5.38M
5
ELOX
Eloxx Pharmaceuticals
ELOX
+$5.1M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$6.99M
2
JBIO
Jade Biosciences
JBIO
+$4.85M
3
PVLA
Palvella Therapeutics
PVLA
+$4.79M
4
UPB
Upstream Bio Inc
UPB
+$3.2M
5
XFOR icon
X4 Pharmaceuticals
XFOR
+$1.79M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$6.81B
$379M 31.16%
6,897,652
– –
ALMS
2
Alumis Inc
ALMS
$1.47B
$179M 14.67%
6,345,219
– –
MLYS icon
3
Mineralys Therapeutics
MLYS
$2.5B
$158M 13.01%
5,871,018
– –
SEPN
4
Septerna Inc
SEPN
$1.72B
$105M 8.66%
3,149,128
– –
ALMR
5
Alamar Biosciences
ALMR
$2.12B
$67.2M 5.52%
+2,480,310
New +$56.1M
NGNE icon
6
Neurogene
NGNE
$753M
$54M 4.44%
1,717,127
– –
KLRS
7
Kalaris Therapeutics
KLRS
$93.8M
$52.4M 4.31%
12,881,175
-66,906
-0.5% -$348K
SGP
8
SpyGlass Pharma
SGP
$970M
$47M 3.86%
2,109,953
– –
STRO icon
9
Sutro Biopharma
STRO
$341M
$35.3M 2.9%
1,062,872
– –
IVA
10
Inventiva
IVA
$1.14B
$23.9M 1.96%
6,314,805
+1,120,000
+22% +$5.38M
JBIO
11
Jade Biosciences
JBIO
$1.26B
$16.4M 1.34%
736,237
-232,561
-24% -$4.85M
PBLS
12
Parabilis Medicines Inc
PBLS
$5.03B
$15.2M 1.25%
+556,044
New +$15.4M
VTVT icon
13
vTv Therapeutics
VTVT
$132M
$11.2M 0.92%
298,496
– –
AQST icon
14
Aquestive Therapeutics
AQST
$671M
$10.4M 0.85%
2,500,000
– –
NKTX icon
15
Nkarta
NKTX
$200M
$9.93M 0.82%
3,507,666
– –
ARTV
16
Artiva Biotherapeutics
ARTV
$544M
$9.26M 0.76%
+954,861
New +$8.7M
RANI icon
17
Rani Therapeutics
RANI
$98.4M
$7.88M 0.65%
10,369,159
+1,869,159
+22% +$1.66M
AGMB
18
AgomAb Therapeutics NV
AGMB
$730M
$7.79M 0.64%
600,000
– –
ABVX
19
Abivax
ABVX
$9.95B
$7.34M 0.6%
55,095
-1,486
-3% -$168K
XFOR icon
20
X4 Pharmaceuticals
XFOR
$401M
$6.52M 0.54%
1,395,587
-436,979
-24% -$1.79M
ELOX
21
Eloxx Pharmaceuticals
ELOX
$48.8M
$5.55M 0.46%
+400,000
New +$5.1M
CHRS icon
22
Coherus Oncology
CHRS
$212M
$4.8M 0.39%
3,428,571
– –
UPB
23
Upstream Bio Inc
UPB
$333M
$2.45M 0.2%
353,717
-382,330
-52% -$3.2M
GOSS icon
24
Gossamer Bio
GOSS
$85.8M
$1.19M 0.1%
7,222,559
– –
ACLX
25
DELISTED
Arcellx
ACLX
– –
-60,873
Closed -$6.99M
1
2

Similar funds

MWA
Monograph Wealth Advisors Manhattan Beach, California $1.22B AUM 24.22% 1-Year Est. Return
SFP
Shepherd Financial Partners Winchester, Massachusetts $1.22B AUM 28.54% 1-Year Est. Return
OCM
Once Capital Management New York $1.22B AUM 87.6% 1-Year Est. Return
TCM
Tributary Capital Management Omaha, Nebraska $1.22B AUM 44.12% 1-Year Est. Return
TCM
Thames Capital Management Roseland, New Jersey $1.22B AUM 391.75% 1-Year Est. Return
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
GGI
Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return
SL
Salomon & Ludwin Richmond, Virginia $1.22B AUM 19.42% 1-Year Est. Return

Samsara BioCapital's Q2 2026 Portfolio in Review

As of Q2 2026, Samsara BioCapital held 26 positions worth $1.22B, up 18% from $1.03B the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Samsara BioCapital deployed $70.2M of net new capital in Q2 2026, opening 4 new positions and adding to 2 existing holdings. Its largest new stake was Alamar Biosciences: 2,480,310 shares worth $67.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Jade Biosciences, an estimated $4.85M trimmed.

  • Samsara BioCapital's largest Q2 2026 buy was Alamar Biosciences: 2,480,310 shares worth $67.2M.
  • Samsara BioCapital added most to Inventiva in Q2 2026, an estimated $5.38M increase.
  • Samsara BioCapital's biggest Q2 2026 reduction was Jade Biosciences, cutting an estimated $4.85M.
  • Samsara BioCapital fully exited Arcellx in Q2 2026, selling an estimated $6.99M.
  • Samsara BioCapital's ten largest holdings make up 90% of its $1.22B portfolio in Q2 2026.
  • Samsara BioCapital opened 4 new positions and closed 2 in Q2 2026.
  • Samsara BioCapital's portfolio value rose 18% quarter-over-quarter to $1.22B.

Based on Samsara BioCapital's 13F filing for Q2 2026, filed 14 Aug 2026.